Meet The Professors: Pancreatic Cancer Edition, 2016 - Video 24Novel approaches under investigation for pancreatic cancer in the neoadjuvant setting
1:37 minutes.
TRANSCRIPTION:
DR LOVE: I’m curious in general. We’ve heard about this concept, particularly in breast cancer, of using — you’ve heard of the I-SPY efforts, et cetera, with Hope Rugo, et cetera. Where do we stand with using the neoadjuvant window to explore new agents? DR TEMPERO: That’s the whole purpose of another trial that’s in the cooperative group, in which gemcitabine and nab paclitaxel preoperatively is being compared to FOLFIRINOX preoperatively. And this is not a bake-off between these regimens, by the way. That’s not the purpose. The purpose of this randomized Phase II trial in the neoadjuvant setting is to benchmark each one of these regimens so that we can understand what the path CR rate is, for example. Once that is benchmarked, we could actually move into something like I-SPY, where new agents are actually introduced in the neoadjuvant setting. And I think that would be a tremendous step forward in the field, because we would be able to have the resection tissue to be able to see what our treatments actually did. And that’s been one of the values of I-SPY. DR LOVE: Interesting. Any thoughts about this strategy, research-wise, Tony? DR BEKAII-SAAB: I think this makes a lot of sense. I mean, we still have a poor understanding of the biology of pancreas cancer, the stromal tumor interactions. I mean, we understand a little bit, but we haven’t really been able to take peeks into what really happens at the tumoral level and at the stromal level in real time. And I think again, establishing these platforms to build on makes a lot of sense. So it will help us not just with the early stage but with the later stages of the disease as well. |